Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a promising biotechnology company with a positive outlook due to its innovative immuno-oncology pipeline and strong financials, including a price target of $9.00 based on a discounted cash flow analysis and projected EPS. Its lead asset, givastomig, has the potential to be a best-in-class CLDN18.2 bispecific antibody with broad potential in the gastric cancer market due to its ability to target low-level CLDN18.2 expression and improved GI tolerability compared to competitors. The company's upcoming Phase 1b data and planned Phase 2b and Phase 3 studies are important milestones to monitor and will help validate the program's added value to NovaBridge's portfolio.

Bears say

NovaBridge Biosciences is well-positioned to execute on its clinical programs, with the FDA endorsement for givastomig and a strong focus on durability with VIS101. However, it is worth noting that the company's financials may be impacted by the extended timelines for clinical development, and the unclear contribution of VEGF versus Ang-2 inhibition raises some uncertainty around the potential success of VIS101 in the market. Overall, there is potential for NovaBridge to succeed in the long term, but short-term challenges and uncertainties may impact its stock performance.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.